Disclosed is the use of a rhodostomin variant comprising an amino acid sequence selected from SEQ ID NO: 1 through SEQ ID NO: 6 or SEQ ID NO: 8 through SEQ ID NO: 16, or a pharmaceutically acceptable salt of said rhodostomin variant, in the manufacture of a medicament for the treatment and/or prevention of an angiogenesis-related eye disease, wherein the medicament is adapted to administer the rhodostomin variant or pharmaceutically acceptable salt of the rhodostomin variant to a human at a dosage of 0.0001pg to about 300µg per eye.
